A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes
Background & aims: This participant-blinded parallel-group randomized placebo-controlled study demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in newly diagnosed type 1 diabetes (T1DM) in children. Methods: Subjects from outpatient clinic were randomized to inte...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier BV
2013
|
Online Access: | http://psasir.upm.edu.my/id/eprint/29701/1/A%20randomized%20placebo.pdf http://psasir.upm.edu.my/id/eprint/29701/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.upm.eprints.29701 |
---|---|
record_format |
eprints |
spelling |
my.upm.eprints.297012015-09-02T04:54:49Z http://psasir.upm.edu.my/id/eprint/29701/ A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes Asal, Ataie Jafari Loke, Seng Cheong Rahmat, Asmah Larijani, Bagher Abbasi, Farzaneh Leow, Melvin Khee Shing Yassin, Zaitun Background & aims: This participant-blinded parallel-group randomized placebo-controlled study demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in newly diagnosed type 1 diabetes (T1DM) in children. Methods: Subjects from outpatient clinic were randomized to intervention and control groups. Inclusion: (1) age 8–15, (2) T1DM, (3) duration <8 weeks, (4) no chronic diseases, (5) stable diet. Exclusion: (1) vitamin D, calcium supplements or fortified foods, (2) hypercalcemia. Intervention group received alfacalcidol 0.25 μg twice daily, while control group received placebo. Insulin given physician-titrated to blood glucose. Safety monitored by serum calcium and phosphate. Beta cell function assessed at 0, 3, 6 months using fasting C-peptide (FCP) and daily insulin dosage per body weight (DID). Primary outcome measured using multivariate repeated measures GLM-ANOVA, with FCP and DID as primary measures and age, gender, sunlight exposure, 25-hydroxy vitamin D, and HbA1c as covariates. Results: Of 61 subjects, 7 dropped out. GLM-ANOVA showed that groups were different (p = 0.019, Eta-squared = 0.087), with no significant covariates. FCP was higher and DID lower in the intervention group, with males having stronger responses to alfacalcidol (p = 0.001). No adverse effects were observed. Conclusions: The study confirmed that alfacalcidol can safely preserve beta cell function in newly diagnosed T1DM in children, with a stronger effect in males. Elsevier BV 2013-12 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/29701/1/A%20randomized%20placebo.pdf Asal, Ataie Jafari and Loke, Seng Cheong and Rahmat, Asmah and Larijani, Bagher and Abbasi, Farzaneh and Leow, Melvin Khee Shing and Yassin, Zaitun (2013) A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clinical Nutrition, 32 (6). pp. 911-917. ISSN 0261-5614; ESSN: 1532-1983 10.1016/j.clnu.2013.01.012 |
institution |
Universiti Putra Malaysia |
building |
UPM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Putra Malaysia |
content_source |
UPM Institutional Repository |
url_provider |
http://psasir.upm.edu.my/ |
language |
English |
description |
Background & aims: This participant-blinded parallel-group randomized placebo-controlled study demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in newly diagnosed type 1 diabetes (T1DM) in children.
Methods: Subjects from outpatient clinic were randomized to intervention and control groups. Inclusion: (1) age 8–15, (2) T1DM, (3) duration <8 weeks, (4) no chronic diseases, (5) stable diet. Exclusion: (1) vitamin D, calcium supplements or fortified foods, (2) hypercalcemia. Intervention group received alfacalcidol 0.25 μg twice daily, while control group received placebo. Insulin given physician-titrated to blood glucose. Safety monitored by serum calcium and phosphate. Beta cell function assessed at 0, 3, 6 months using fasting C-peptide (FCP) and daily insulin dosage per body weight (DID). Primary outcome measured using multivariate repeated measures GLM-ANOVA, with FCP and DID as primary measures and age, gender, sunlight exposure, 25-hydroxy vitamin D, and HbA1c as covariates.
Results: Of 61 subjects, 7 dropped out. GLM-ANOVA showed that groups were different (p = 0.019, Eta-squared = 0.087), with no significant covariates. FCP was higher and DID lower in the intervention group, with males having stronger responses to alfacalcidol (p = 0.001). No adverse effects were observed.
Conclusions: The study confirmed that alfacalcidol can safely preserve beta cell function in newly diagnosed T1DM in children, with a stronger effect in males. |
format |
Article |
author |
Asal, Ataie Jafari Loke, Seng Cheong Rahmat, Asmah Larijani, Bagher Abbasi, Farzaneh Leow, Melvin Khee Shing Yassin, Zaitun |
spellingShingle |
Asal, Ataie Jafari Loke, Seng Cheong Rahmat, Asmah Larijani, Bagher Abbasi, Farzaneh Leow, Melvin Khee Shing Yassin, Zaitun A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
author_facet |
Asal, Ataie Jafari Loke, Seng Cheong Rahmat, Asmah Larijani, Bagher Abbasi, Farzaneh Leow, Melvin Khee Shing Yassin, Zaitun |
author_sort |
Asal, Ataie Jafari |
title |
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
title_short |
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
title_full |
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
title_fullStr |
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
title_full_unstemmed |
A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
title_sort |
randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes |
publisher |
Elsevier BV |
publishDate |
2013 |
url |
http://psasir.upm.edu.my/id/eprint/29701/1/A%20randomized%20placebo.pdf http://psasir.upm.edu.my/id/eprint/29701/ |
_version_ |
1643829839135768576 |
score |
13.188404 |